Zevra Q2 net revenue $25.9M, net income $74.7M on PRV sale; adjusted net loss $3.2M

ZEVRA THERAPEUTICS, INC.

2025-Q2 EPS reported $1.16 revenue$46,282,000

Product net revenue $21.8M (MIPLYFFA $21.5M, OLPRUVA $0.3M) vs $4.4M total revenue in Q2 2024.
Closed sale of PRV for $150.0M on April 1, boosting cash to $217.7M as of June 30.
Non-cash impairment of OLPRUVA intangible assets $58.7M and inventory obsolescence $11.7M.
Adjusted net loss $(3.2)M ($(0.06)/share) excluding PRV sale and impairment charges.
MIPLYFFA launch: 7 new enrollment forms in Q2, total 129 since launch; market access 52%.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.